Skip Navigation



BJA Advance Access published online on July 28, 2005

British Journal of Anaesthesia, doi:10.1093/bja/aei210
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
95/4/434    most recent
aei210v1
Right arrow E-Letters: Submit a response to the article
Right arrow E-letters: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gillman, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gillman, P. K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Board of Management and Trustees of the British Journal of Anaesthesia 2005. All rights reserved. For Permissions, please e-mail: journal.permissions@oupjournals.org

Review Article

Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity

P. K. Gillman 1*

1 Pioneer Valley Private Hospital, Mackay, Queensland 4740, Australia

* To whom correspondence should be addressed.
P. K. Gillman, E-mail: kg{at}matilda.net.au


   Abstract

Toxicity resulting from excessive intra-synaptic serotonin, historically referred to as serotonin syndrome, is now understood to be an intra-synaptic serotonin concentration-related phenomenon. Recent research more clearly delineates serotonin toxicity as a discreet toxidrome characterized by clonus, hyper-reflexia, hyperthermia and agitation. Serotonergic side-effects occur with serotonergic drugs, and overdoses of serotonin re-uptake inhibitors (SRIs) frequently produce marked serotonergic side-effects, and in 15% of cases, moderate serotonergic toxicity, but not to a severe degree, which produces hyperthermia and risk of death. It is only combinations of serotonergic drugs acting by different mechanisms that are capable of raising intra-synaptic serotonin to a level that is life threatening. The combination that most commonly does this is a monoamine oxidase inhibitor (MAOI) drug combined with any SRI. There are a number of lesser-known drugs that are MAOIs, such as linezolid and moclobemide; and some opioid analgesics have serotonergic activity. These properties when combined can precipitate life threatening serotonin toxicity. Possibly preventable deaths are still occurring. Knowledge of the properties of these drugs will therefore help to ensure that problems can be avoided in most clinical situations, and treated appropriately (with 5-HT2A antagonists for severe cases) if they occur. The phenylpiperidine series opioids, pethidine (meperidine), tramadol, methadone and dextromethorphan and propoxyphene, appear to be weak serotonin re-uptake inhibitors and have all been involved in serotonin toxicity reactions with MAOIs (including some fatalities). Morphine, codeine, oxycodone and buprenorphine are known not to be SRIs, and do not precipitate serotonin toxicity with MAOIs.

Keywords: analgesics, opioid; complications, serotonin toxicity syndrome; pharmacology, MAO inhibitors; serotonin re-uptake inhibitor.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
S. Jamison and S. Vasudeva
A 60-year-old woman with agitation and psychosis following ingestion of dextromethorphan and opioid analgesics
J Psychopharmacol, November 1, 2009; 23(8): 989 - 991.
[Abstract] [PDF]


Home page
J Child NeurolHome page
S. Hatherill and A. Flisher
Delirium in Children With HIV/AIDS
J Child Neurol, July 1, 2009; 24(7): 879 - 883.
[Abstract] [PDF]


Home page
ChestHome page
B. L. Erstad, K. Puntillo, H. C. Gilbert, M. J. Grap, D. Li, J. Medina, R. A. Mularski, C. Pasero, B. Varkey, and C. N. Sessler
Pain Management Principles in the Critically Ill
Chest, April 1, 2009; 135(4): 1075 - 1086.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
R. G Wenzel, S. Tepper, W. E Korab, and F. Freitag
Serotonin Syndrome Risks When Combining SSRI/SNRI Drugs and Triptans: Is the FDA's Alert Warranted?
Ann. Pharmacother., November 1, 2008; 42(11): 1692 - 1696.
[Abstract] [Full Text] [PDF]


Home page
ICVTSHome page
I. Koniari, G. Tsigkas, and E. Apostolakis
eComment: Serotonin syndrome: pharmacogenomics and treatment
Interactive CardioVascular and Thoracic Surgery, August 1, 2008; 7(4): 657 - 658.
[Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
N Jackson, J Doherty, and S Coulter
Neuropsychiatric complications of commonly used palliative care drugs
Postgrad. Med. J., March 1, 2008; 84(989): 121 - 126.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
M. Steinberg and A. K. Morin
Mild serotonin syndrome associated with concurrent linezolid and fluoxetine
Am. J. Health Syst. Pharm., January 1, 2007; 64(1): 59 - 62.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
A. P. Hall and J. A. Henry
Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management
Br. J. Anaesth., June 1, 2006; 96(6): 678 - 685.
[Abstract] [Full Text] [PDF]

E-letters:

Read all E-letters

The dangers of antidepressants
Sandip Patel, et al.
British Journal of Anaesthesia, 17 Oct 2005 [Full text]
Fentanyl and serotonin toxicity
P Ken Gillman, et al.
British Journal of Anaesthesia, 12 Mar 2009 [Full text]
Re: The dangers of antidepressants
P Ken Gillman
British Journal of Anaesthesia, 12 Mar 2009 [Full text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.